[LCID Study Number: 20193146]

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) for Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

The purpose of this study is to see if we can lower the chance of your endometrial cancer growing or spreading by adding a new immunotherapy drug to the usual combination of chemotherapy drugs.

Disease/Condition: Endometrial Cancer, Uterine Corpus Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody; Winchester Hospital

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421